Ocular Therapeutix Inc OCUL

NAS: OCUL | ISIN: US67576A1007 26/04/2024

4,745 USD (+12,98%)

(+12,98%) 26/04/2024

Grafiek Ocular Therapeutix Inc

Grafiek Ocular Therapeutix Inc

1 dag1d 12,98%
1 week1w -6,50%
1 maand1m -49,03%
3 maanden3m -7,14%
6 maanden6m 96,07%
1 jaar1j -21,05%
5 jaar5j 20,74%

Ocular Therapeutix Inc in het nieuws

Toon enkel gratis nieuws

19 februari 2024 · AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis · Persbericht

31 oktober 2023 · AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery · Persbericht

13 april 2022 · AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery · Persbericht

Profiel Ocular Therapeutix Inc

Fabricage van farmaceutische preparaten

Farmaceutische producten: Andere

Gezondheidstechnologie

Website: www.ocutx.com

Hoofdzetel: Bedford, Massachusetts Verenigde Staten

CEO: Antony Mattessich

Werknemers: 274

Aandelen Ocular Therapeutix Inc

Beurswaarde: 734,07 miljoen USD

Effecten: 154,70 miljoen

Winst per aandeel (12 maand): PLUS

Beta: 1,87

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe